Yoshiya Tanaka Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

3/2024	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
3/2024	TYK2: an emerging therapeutic target in rheumatic disease.
2/2024	Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
12/2023	Validation of claims-based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE-J study.
8/2023	Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
1/2023	Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
1/2023	High-fat-diet-associated intestinal microbiota exacerbates psoriasis-like inflammation by enhancing systemic γδ T cell IL-17 production.
1/2023	Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
1/2022	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study.
1/2021	Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshiya Tanaka Research Topics

Disease

328	Rheumatoid Arthritis 04/2024 - 07/2001
86	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2024 - 10/2003
50	Type 2 Diabetes Mellitus (MODY) 04/2024 - 06/2005
45	Infections 04/2024 - 02/2004
37	Autoimmune Diseases (Autoimmune Disease) 03/2024 - 02/2002
36	Neoplasms (Cancer) 04/2024 - 01/2002
35	Osteoporosis 03/2024 - 06/2003
34	Inflammation (Inflammations) 04/2024 - 07/2001
26	Herpes Zoster 04/2024 - 01/2016
23	Psoriatic Arthritis 04/2024 - 07/2016
21	Hypoglycemia (Reactive Hypoglycemia) 12/2023 - 02/2006
19	Immunoglobulin G4-Related Disease 12/2023 - 02/2012
15	Arthritis (Polyarthritis) 03/2024 - 02/2004
15	Necrosis 02/2024 - 08/2012
15	Pathologic Processes 01/2022 - 03/2002
14	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024 - 01/2004
14	Hyperglycemia 12/2023 - 06/2005
14	Bone Resorption 10/2023 - 08/2002
13	Pain (Aches) 10/2023 - 03/2013
12	Rheumatic Diseases (Rheumatism) 09/2020 - 01/2007
11	Systemic Scleroderma (Systemic Sclerosis) 04/2024 - 07/2015
10	Lupus Nephritis 11/2023 - 01/2016
9	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2023 - 06/2002
9	Bone Fractures (Bone Fracture) 11/2019 - 06/2003
8	Drug-Related Side Effects and Adverse Reactions 12/2023 - 10/2011
8	Body Weight (Weight, Body) 11/2023 - 10/2008
8	Fibrosis (Cirrhosis) 03/2023 - 10/2009
8	Hypercalcemia (Milk Alkali Syndrome) 10/2020 - 01/2004
7	Fatigue 01/2024 - 11/2017
7	Graves Disease (Basedow Disease) 05/2023 - 01/2014
7	Dermatomyositis (Dermatopolymyositis) 11/2022 - 01/2008
7	Vascular Calcification 01/2019 - 08/2006
7	Diabetes Mellitus 01/2017 - 06/2006
7	Atherosclerosis 05/2016 - 05/2003
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 04/2024 - 01/2015
6	Mixed Connective Tissue Disease (MCTD) 04/2024 - 01/2005
6	Disease Progression 09/2023 - 07/2004
6	Atopic Dermatitis (Atopic Eczema) 08/2023 - 07/2013
6	Pulmonary Arterial Hypertension 07/2023 - 01/2020

Drug/Important Bio-Agent (IBA)

87	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 12/2002
54	Antirheumatic Agents (DMARD)IBA 04/2024 - 02/2004
53	GlucocorticoidsIBA 03/2024 - 06/2003
50	Janus Kinase InhibitorsIBA 04/2024 - 01/2012
43	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 01/2006
36	CytokinesIBA 01/2024 - 07/2001
35	Adalimumab (Humira)FDA Link 04/2024 - 06/2012
32	baricitinibIBA 07/2023 - 03/2016
31	tofacitinibIBA 12/2023 - 08/2011
31	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2023 - 06/2005
28	tocilizumab (atlizumab)FDA Link 11/2023 - 04/2011
25	Monoclonal AntibodiesIBA 01/2023 - 01/2008
23	Tumor Necrosis Factor InhibitorsIBA 04/2024 - 07/2011
22	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2005
21	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2009
21	Abatacept (Orencia)FDA Link 11/2023 - 01/2014
21	Janus KinasesIBA 10/2023 - 01/2014
19	Etanercept (Enbrel)FDA Link 01/2023 - 01/2009
19	Interleukin-6 (Interleukin 6)IBA 01/2023 - 11/2007
19	Diphosphonates (Bisphosphonates)IBA 05/2021 - 11/2002
18	Immunoglobulin G (IgG)IBA 03/2023 - 02/2012
17	AutoantibodiesIBA 12/2021 - 12/2002
16	peficitinibIBA 12/2023 - 06/2016
16	Infliximab (Remicade)FDA Link 11/2021 - 01/2007
15	GLPG0634IBA 12/2023 - 01/2021
14	upadacitinibIBA 04/2024 - 01/2019
14	Prednisolone (Predate)FDA LinkGeneric 04/2024 - 02/2004
14	Rituximab (Mabthera)FDA Link 09/2023 - 01/2007
14	Insulin (Novolin)FDA Link 11/2022 - 06/2005
14	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2013
13	AntibodiesIBA 04/2024 - 06/2011
13	Denosumab FDA Link 12/2023 - 05/2010
13	Certolizumab Pegol FDA Link 07/2023 - 07/2014
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2023 - 10/2003
11	DNA (Deoxyribonucleic Acid)IBA 05/2023 - 10/2003
11	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 03/2018 - 12/2004
10	SteroidsIBA 03/2024 - 10/2003
10	belimumabIBA 11/2023 - 01/2018
10	anifrolumabIBA 11/2023 - 01/2020
10	sarilumabIBA 08/2023 - 09/2014
9	Interleukin-17 (Interleukin 17)IBA 03/2024 - 03/2011
9	C-Reactive ProteinIBA 12/2023 - 12/2006
9	Proteins (Proteins, Gene)FDA Link 10/2023 - 06/2005
9	InterferonsIBA 08/2023 - 06/2012
9	Hemoglobins (Hemoglobin)IBA 04/2022 - 03/2005
8	Vitamin D FDA LinkGeneric 04/2024 - 12/2012
8	InterleukinsIBA 03/2024 - 12/2014
7	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 09/2023 - 01/2020
7	Phosphotransferases (Kinase)IBA 08/2023 - 11/2012
7	Immunosuppressive Agents (Immunosuppressants)IBA 07/2023 - 10/2006
7	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 12/2012
7	AntigensIBA 01/2021 - 08/2002
7	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 12/2020 - 04/2013
6	bimekizumabIBA 02/2024 - 01/2023
6	LipidsIBA 02/2023 - 10/2008
6	quetmolimabIBA 01/2023 - 01/2018

Therapy/Procedure

166	Therapeutics 03/2024 - 09/2002
10	Remission Induction 01/2023 - 02/2004
9	Glycemic Control 02/2023 - 06/2006
8	Precision Medicine 04/2023 - 07/2016
6	Drug Therapy (Chemotherapy) 03/2023 - 07/2004